Spyre Therapeutics, Inc. Common Stock
Symbol: SYRE (NASDAQ)
22.89
▲ (3.04%) 0.675
Company Description:
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Key Stats
- Today's Open: $22.19
- Today's High: $22.807
- Today's Low: $22.01
- Today's Volume: 197.89K
- Yesterday Close: $22.21
- Yesterday High: $23.3975
- Yesterday Low: $21.88
- Yesterday Volume: 906.70K
- Last Min Volume: 56
- Last Min High: $22.795
- Last Min Low: $22.789
- Last Min VWAP: $22.794
Company Profile
- Name: Spyre Therapeutics, Inc. Common Stock
- Website: https://www.spyre.com
- Listed Date: 2016-04-07
- Location: WALTHAM, MA
- Market Status: Active
- CIK Number: 0001636282
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $1.80B
- Round Lot: 100
- Outstanding Shares: 77.50M
- Asset Type: CS
RECENT FILINGS FOR SYRE
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-17 | SCHEDULE 13D/A | View |
| 2025-10-15 | 8-K | View |
| 2025-10-14 | 424B5 | View |
| 2025-10-14 | 424B5 | View |
| 2025-10-14 | 8-K | View |
| 2025-09-03 | 4 | View |
| 2025-08-05 | S-8 | View |
| 2025-08-05 | 8-K | View |
| 2025-08-05 | 10-Q | View |
| 2025-07-29 | SCHEDULE 13G | View |
| 2025-07-16 | SCHEDULE 13G/A | View |
| 2025-06-17 | 8-K | View |
| 2025-06-02 | 4 | View |
| 2025-06-02 | 4 | View |
| 2025-06-02 | 4 | View |
| 2025-06-02 | 4 | View |
| 2025-06-02 | 4 | View |
| 2025-06-02 | 4 | View |
| 2025-06-02 | 8-K | View |
| 2025-06-02 | UPLOAD | View |
Latest News on SYRE